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Abstract 36 
Background: Resection of colorectal cancer (CRC) initiates inflammation, mediated 37 
at least partly by NFĸB (nuclear factor kappa-light-chain-enhancer of activated B-38 
cells), leading to muscle catabolism and reduced physical performance. 39 
Eicosapentaenoic acid (EPA) has been shown to modulate NFĸB, but evidence for its 40 
benefit around the time of surgery is limited. 41 
Objective: To assess the effect of EPA supplementation on muscle inflammation and 42 
physical function around the time of major surgery. 43 
Design: In a double-blind randomized control trial, 61 patients (age: 68.3±0.95 y; 42 44 
male) scheduled for CRC resection, received 3g per day of EPA (n=32) or placebo 45 
(n=29) for 5-days before and 21-days after operation. Lean muscle mass (LMM) (via 46 
dual energy X-ray absorptiometry (DXA)), anaerobic threshold (AT) (via 47 
cardiopulmonary exercise testing (CPET)) and hand-grip strength (HG) were 48 
assessed before and 4-weeks after surgery, with muscle biopsies (m. vastus lateralis) 49 
obtained for the assessment of NF-ĸB protein expression. 50 
Results: There were no differences in muscle NFĸB between EPA and placebo 51 
groups (mean difference (MD) -0.002; 95% confidence interval (CI) -0.19 to 0.19); 52 
p=0.98). There was no difference in LMM (MD 704.77g; 95% CI -1045.6g to 2455.13g; 53 
p=0.42) or AT (MD 1.11 mls/kg/min; 95% CI -0.52 mls/kg/min to 2.74 mls/kg/min; 54 
p=0.18) between the groups. Similarly, there was no difference between the groups in 55 
HG at follow up (MD 0.1; 95% CI -1.88 to 2.08; p=0.81). Results were similar when 56 
missing data was imputed. 57 
Conclusion: EPA supplementation confers no benefit in terms of inflammatory status, 58 
as judged by NFĸB, or preservation of LMM, aerobic capacity or physical function 59 
following major colorectal surgery. 60 
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Introduction 65 
With an estimated 1.4 million cases per annum worldwide  [1] colorectal cancer (CRC) 66 
represents a major clinical burden, often resulting in morbidity and death. Surgical 67 
resection remains the only known cure for CRC. Despite an increased proportion of 68 
resections being performed laparoscopically, in the United Kingdom 39.2% are still 69 
resected via open surgery with a further 8.5% of laparoscopic procedures converted 70 
to open surgery [2]. This exposes an often elderly and frail patient population to a 71 
major physiological challenge. To exemplify the magnitude of this challenge, surgery 72 
for CRC confers a risk of death of 3.8% at 90 days [2] and considerable morbidity, with 73 
length of hospital stay typically five or more days [3]. Moreover, 30 day re-admission 74 
rate following CRC surgery remains high at 10% [2].  75 
 76 
The inflammatory responses associated with major body cavity surgery have been 77 
implicated in the initiation and maintenance of an acute phase response, and in 78 
countering the cellular processes important in the preservation of skeletal muscle [4]. 79 
This has led to research attempting to modulate these inflammatory responses 80 
through immuno-nutritional supplementation in the perioperative period. However, to 81 
date these efforts have reported variable results [5-8]. Eicosapentaenoic acid (EPA), 82 
an omega-3 long chain polyunsaturated fatty acid, has been advocated as one such 83 
nutritional supplement that may diminish the stress response and lessen the stress-84 
related burden of operation in a cachectic cancer population. EPA has been proposed 85 
as an agent which may ameliorate post-operative inflammation and subsequent 86 
muscle catabolism via a variety of mechanisms [9]. EPA supplementation has been 87 
shown to reduce serum concentrations of pro-inflammatory agents [7, 10] and the 88 
activity of tumour derived proteolysis inducing factor [7, 11]. In addition, EPA is thought 89 
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to exert anti-inflammatory activity through its activation of the inflammatory regulatory 90 
gene peroxisome proliferator activated receptor (PPAR)- which can inhibit nuclear 91 
factor kappa-light-chain-enhancer of activated B-cells (NFκB) activity [12], and also 92 
via its inhibition of tumour necrosis factor (TNF)-α induced activation of caspase 93 
pathways of muscle catabolism [11]. 94 
 95 
Whilst a number of pre-clinical trials have investigated the immuno-modulation 96 
properties of EPA in a cachectic cancer population, few have addressed its use in the 97 
perioperative patient [13-16]. The aims of this study were therefore, to determine the 98 
effects of perioperative EPA supplementation on perioperative inflammation, muscle 99 
loss, and functional and clinical outcomes in CRC patients. 100 
 101 
Methods 102 
Trial design 103 
This was a single centre, double-blind, placebo-controlled, parallel-group study, 104 
conducted in the United Kingdom. Patients were randomly assigned 1:1, using 105 
computerised randomisation (www.randomiser.org), to receive either EPA, or near 106 
identical placebo capsules, for 5 days prior to surgery and for 21 days post-operatively. 107 
Treatment assignment was unknown to the investigators, patients, trial statistician and 108 
treating surgical team. 109 
 110 
Patients were asked to attend the University of Nottingham Clinical, Metabolic & 111 
Molecular Physiology laboratories in Derby following an overnight fast (water ad 112 
libitum) one week prior to surgery (visit 1 (V1); timed to coincide with the routine care 113 
pre-operative assessment visit) and again 4 weeks after surgery (V2). The 114 
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supplementation period of 21-days determining the timing of V2 was based on 115 
previous work [6] demonstrating this time-point to be the nadir in hand-grip strength 116 
(HG), total body protein and body weight following major abdominal surgery.  117 
 118 
At both study visits body composition was first analysed by dual-energy x-ray 119 
absorptiometry (DXA; Lunar Prodigy II, GE Medical Systems). Cardiopulmonary 120 
exercise testing (CPET) (ZAN680, nSpire Health, UK) and HG dynamometry (Hand-121 
grip Dynamometer Digital A5401, Takei, Japan) were then performed after a 122 
standardized light breakfast. A muscle biopsy was taken under local anaesthesia 123 
(lidocaine 1%) from the m. vastus lateralis using our standard conchotome technique 124 
[28] on the day of surgery (within five minutes of induction of anaesthesia) and 125 
repeated 5-weeks after surgery. The second biopsy was taken one week after V2 to 126 
prevent any acute effect of intense exercise (the CPET) on muscle sample analysis.  127 
 128 
Patients were reviewed throughout the perioperative period with vital signs and HG 129 
recorded for 5 days post-operation. 130 
 131 
Study participants 132 
Patients presenting to the CRC multidisciplinary team meeting at the Royal Derby 133 
Hospital, who met inclusion/exclusion criteria were approached for recruitment when 134 
they attended hospital as an out-patient prior to surgery. Eligible patients were those 135 
scheduled for open elective CRC resection surgery with curative intent; right hemi-136 
colectomy, left hemi-colectomy or anterior resection, who had not received neo-137 
adjuvant chemoradiotherapy. All patients had open CRC resection, with anaesthetic 138 
technique at the discretion of the anaesthetist. Exclusion criteria were: intended 139 
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laparoscopic resection, abdominoperineal resection of the rectum, previous chemo or 140 
radiotherapy, peripheral neuropathy/myopathy, unstable angina, myocardial infarction 141 
within 3 months, severe aortic stenosis, chronic heart failure, New York Heart 142 
Association class 3 or above, severe COPD, emphysema, fibrosing alveolitis, 143 
interstitial lung disease, current fish-oil derived nutritional supplement or known 144 
metastatic disease. Patients having laparoscopic surgery were expected to have a 145 
less marked stress response from surgery and those having abdominoperineal 146 
resection or neo-adjuvant chemotherapy were deemed to likely have markedly greater 147 
stress responses, hence these exclusion criteria. Patients were instructed not to 148 
undertake strenuous exercise and/or intramuscular injections within 48-hours of either 149 
study visit. Before commencing the study, all patients were screened using a medical 150 
questionnaire, physical examination and resting ECG.  151 
 152 
The study was conducted according to the Declaration of Helsinki under the auspices 153 
of an NHS Research Ethics Committee (REC 11/EM/0066) and was registered at 154 
ClinicalTrials.gov (NCT01320319). All patients gave their written, informed consent to 155 
participate in the study. 156 
 157 
Nutritional intervention  158 
500mg capsules of EPA (Minami Nutrition, Belgium) or near identical placebo capsules 159 
(Wassen Nutrition, UK) (EPA (Eicosapentaenoic Acid) 500 mg, DHA 160 
(Docosahexaenoic Acid) 0 mg, Other Omega-3s 27 mg, Omega-6 Fatty Acids 0 mg) 161 
were dispensed by the hospital pharmacy, with a daily regimen of 1g three times a day 162 
(tds) prescribed. Treatment regimen was for 5 days pre-operatively and for 21 days 163 
following surgery. Patients were supplied with a fixed number of excess capsules and 164 
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were asked to return the remaining capsules on V2 for pharmacy determination of 165 
compliance.  166 
 167 
Outcomes 168 
The primary outcome measures of this study were the effect of EPA supplementation 169 
on changes in i) cardiorespiratory fitness, ii) physical strength, iii) lean muscle mass 170 
(LMM) and iv) cellular markers of inflammation, in the perioperative period. Secondary 171 
outcomes were based on perioperative care data which was collected in the first 5 172 
days following surgery. This data comprised temperature, white cell count, and post-173 
operative complication scoring [17]. Additional data regarding length of hospital stay 174 
(LoS) was recorded following a retrospective analysis of patient notes at V2. 175 
 176 
Assessment of Physical Function  177 
On both study visits patients completed CPET supervised by an Advanced Life 178 
Support (ALS) certified clinician. CPET was performed using a Lode Corival cycle 179 
ergometer (ZAN680, nSpire Health, UK) and our standard ramp protocol [18]. In brief, 180 
after a two-minute warm-up, cycling workload was increased in a ramp manner of 20W 181 
per minute, with patients instructed to maintain a cadence of 60-70 rpm. Patients were 182 
encouraged to exercise to 85% or more of age-predicted maximal heart rate (220-age) 183 
and to a respiratory exchange ratio (RER; VCO2/VO2) above 1.1. Tests were 184 
terminated when patients were unable to maintain a cycling cadence of >60rpm, or 185 
reported volitional exhaustion. On completion of the study anaerobic threshold (AT) 186 
was calculated by two independent trained assessors using the V-slope method [19] 187 
and determined as the mean of these two values. 188 
 189 
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HG was determined by dynamometry as the highest reading of three attempts at 190 
maximal contraction with the dominant hand, using a digital hand-grip dynamometer 191 
(Takei, Japan). Measurements of HG were taken on V1 and V2, and on each of the 192 
first five post-operative days (POD), or until hospital discharge, whichever occurred 193 
first. 194 
 195 
Assessment of Cellular Markers of Inflammation  196 
Muscle protein expression of NFκB was determined from biopsy tissue (10–20mg) of 197 
the m. vastus lateralis using our standard immunoblotting techniques [20] with a 198 
primary antibody for NFĸB (New England Biolabs, UK). Blots were imaged and 199 
quantified by assessing peak density after ensuring the band was within the linear 200 
range of detection using the ChemiDoc XRS system (Bio-Rad, UK).  201 
 202 
Sample size and statistical analysis 203 
Based on previous data [20] our power calculation suggested that to detect a clinically 204 
(>30%) important difference in NFĸB muscle protein expression between the two 205 
groups (with a two-sided 5% significance level and a power of 80%), a sample size of 206 
28 patients in each group was needed. The study was therefore powered to have 56 207 
patients in total. Accounting for an assumed drop-out rate of 20% a target recruitment 208 
of 70 patients was established.  209 
 210 
Normality was tested using histograms and the Shapiro-Wilk test. If normality was 211 
violated, then non-parametric tests or appropriate transformations were conducted. 212 
Data compared at one time point were analysed using t-tests or Mann-U-Whitney tests 213 
as appropriate. For primary outcomes measured at two time points, we tested the 214 
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difference between each group using ANCOVA, with baseline values as the covariate. 215 
We assessed normality of residuals using histograms. Homogeneity of variance was 216 
assessed using Levene’s robust test statistic. We also tested the assumptions of 217 
linearity, homoscedasticity and homogeneity of regression slopes using the 218 
appropriate plots. For variables measured at multiple time points, we performed linear 219 
mixed models with random intercepts and slopes. An unstructured covariance 220 
structure was used. Time was fitted with a quadratic term for temperature due to non-221 
linearity. Assumptions tested include normality of residuals, linearity and 222 
homoscedasticity. The Dindo-Clavien post-operative complication score was 223 
compared between the two groups using Fisher’s Exact Test. 224 
 225 
In addition to the main available case analysis, we also conducted a sensitivity 226 
analysis with an intention to treat analysis. This was carried out on all randomised 227 
patients with baseline data. The mechanism of missingness was explored. Multiple 228 
imputations (M=20) were performed under the Missing At Random assumption [21] 229 
for all primary outcomes and analysed using linear mixed models.  230 
 231 
Results from analyses are presented as mean differences (MD) with 95% confidence 232 
intervals (CI). NFĸB muscle protein is presented as the natural logarithmic 233 
transformation due to non-normality. All statistical analyses were conducted using 234 
STATA (StataCorp, Texas USA) by a Derby Clinical Trials Unit statistician and a 235 
member of the research team (BD).  236 
 237 
 238 
 239 
12 
 
 
 240 
Results 241 
Recruitment 242 
One hundred and twenty patients were assessed for eligibility and from these 64 were 243 
recruited and randomised to the study; 32 to EPA and 32 to placebo, with baseline 244 
data collected for 32 EPA and 29 placebo patients (Table 1). By cessation of the study, 245 
31 EPA patients and 25 placebo patients had fully completed the study with both 246 
muscle biopsies (Figure 1). An intention to treat analysis was performed on all patients 247 
achieving baseline data for primary outcomes, with missing data imputed on sensitivity 248 
analysis. 249 
 250 
Baseline data  251 
There were no baseline differences in age, height, gender, body weight, or LMM 252 
between the groups. Similarly, both groups were equally matched for operation 253 
performed and cancer staging (Table 1). 254 
 255 
Compliance 256 
Intervention compliance was almost identical between the two groups (EPA: 136±6.33 257 
(87%) vs. placebo: 137±7.57 (88%) capsules consumed, p=0.68). 258 
 259 
Primary outcomes 260 
Muscle protein expression of NF-κB (arbitrary units) showed no difference between 261 
EPA and placebo groups when adjusting for baseline values  (MD -0.002; 95% CI -262 
0.19 to 0.19); p=0.98). 263 
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There were no differences between the EPA and placebo group in whole-body LMM 264 
following CRC resection when adjusting for baseline values (MD 704.77g; 95% CI -265 
1045.6g to 2455.13g; p=0.42) (Figure 2). There was no difference between the groups 266 
in hand grip strength at follow up (MD 0.1; 95% CI -1.88 to 2.08; p=0.81). Furthermore, 267 
there was no difference between the groups for AT when adjusting for baseline values 268 
(MD 1.11 mls/kg/min; 95% CI -0.52 mls/kg/min to 2.74 mls/kg/min; p=0.18).  269 
 270 
Secondary outcomes 271 
There was no significant differences between the groups in postoperative temperature 272 
(p=0.67) (Figure 3A). In addition, there was no significant difference in white cell count 273 
between the groups (p=0.83) (Figure 3B). LoS did not significantly differ between the 274 
groups (EPA: 7.5 days (6-13.5) vs. placebo: 3.82 days (5-10), p=0.41). There was no 275 
difference between the groups in complications (p=0.62). 276 
 277 
Sensitivity analysis 278 
When re-analysing primary outcomes using multiple imputation, similar to the main 279 
analysis, there was no significant differences for NF-κB (p=0.82), LMM (p=0.74), HG 280 
(p=0.53) and AT (p=0.84). 281 
 282 
  283 
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Discussion 284 
This study has shown that perioperative EPA is safe and tolerable for CRC patients. 285 
However, it did not show perioperative EPA to benefit patients having resection of 286 
CRC. 287 
 288 
Surgery is known to elicit a marked physiological stress response, and in this study 289 
patients in both EPA and placebo groups displayed increases in white cell count after 290 
operation which returned to normal by five days post-surgery. In tandem with this HGS 291 
was reduced in the immediate post-operative period, with these reductions extending 292 
up to four weeks after operation. Similarly, whole-body LMM was also reduced over 293 
the same time-frame, although there was no difference between the groups.  294 
 295 
Despite these reductions in muscle mass and muscle function, we failed to detect a 296 
statistically significant or clinically meaningful reduction in cardiorespiratory fitness, a 297 
known risk factor for poor post-operative outcomes. In addition, and at odds with our 298 
previous observations, we also found no change in NFĸB around the time of CRC 299 
resection [22]. 300 
 301 
Furthermore, addressing our primary study aim, nutritional supplementation with EPA 302 
conferred no advantage in terms of body composition, physical performance or clinical 303 
outcomes (LoS and postoperative complications); although it must be acknowledged 304 
that this study was not statistically powered for clinical variables. 305 
  306 
These findings are in contrast to those of previous studies which have suggested 307 
potential beneficial effects of EPA in the both the pre and post-operative period [10, 308 
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23-25]. However, not all EPA trials have reported positive findings. A recent 309 
randomised control trial of standard diet versus standard diet supplemented with 310 
ProSure® (compromising supplementation with 2.2g EPA per day) found no difference 311 
in bodyweight at 1 or 3 months post-operatively between the treatment and control 312 
groups [23]. Similarly, in a separate study, EPA supplementation in CRC, providing 2g 313 
of EPA daily, did not show any benefit of EPA on clinical outcomes of complications, 314 
length of stay or hospital re-admissions [25].  315 
 316 
We have previously shown elevated expression of NFĸB, a key modulator of 317 
inflammation, in the skeletal muscle of CRC patients while the cancer is in situ, with a 318 
return to normality following curative CRC resection [22]. This finding combined with 319 
pre-clinical studies showing attenuated NFĸB activity by EPA [12], is what led us to 320 
this study. However, in this present study we did not show this reduction in muscle 321 
NFĸB after surgery and this may be explained by a number of factors. Firstly, almost 322 
half of the patients in this study had a documented post-operative complication 323 
compared to none in our previous work; this higher complication rate is likely explained 324 
by the inclusion of anterior resections. Anterior resection is a more physiologically 325 
challenging operation, evidenced by the prolonged LoS in this subgroup following 326 
surgery. This may, in turn, have led to continued inflammatory and stress responses 327 
to surgery in these patients, resulting in maintained heightened NFĸB within the 328 
muscle. In addition, in contrast to our earlier work, in this study muscle biopsies were 329 
taken at five weeks post-surgery (as opposed to six weeks previously). At this time-330 
point any inflammation associated with surgery and/or the primary tumour may be 331 
more pronounced, leading to a limited reduction in NFĸB.  332 
 333 
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Our finding of no effect of EPA supplementation on inflammatory status is in contrast 334 
to previous reports which have demonstrated that EPA supplementation decreases 335 
the expression of, and modulates the action of key pro-inflammatory cytokines 336 
(namely TNF-α and IL-6) in human preclinical in vitro models and healthy human 337 
volunteers [26]. Furthermore, EPA supplementation has been reported to attenuate 338 
inflammation in patients with disseminated cancer [27], with several studies reporting 339 
reductions in blood borne pro-inflammatory cytokines one week post-operatively 340 
following EPA supplementation after major gastrointestinal surgery [24, 28, 29]. 341 
Similarly, reductions in LoS of have also been reported with EPA supplementation 342 
following major gastrointestinal surgery [29-31] 343 
 344 
Given our previous experience and that of others, failing to observe an effect of EPA 345 
on expression of NFκB expression is surprising. Previous studies have however 346 
looked at blood borne markers of inflammation, raising the question of EPA 347 
penetrance and its action at the level of skeletal muscle. Normalisation of inflammatory 348 
markers within the muscle will likely follow on from, rather than precede inflammatory 349 
changes within the plasma. This temporal factor may account for the absence of an 350 
observed reduction in tissue inflammation five weeks post-surgery. Indeed, within this 351 
time-frame muscle mass and physical performance were still diminished compared to 352 
pre-operative measures, suggesting that skeletal muscle function, structure and 353 
possibly metabolism [32-33] , were not normalised by this point. 354 
 355 
We accept that there are number of limitations to this study. The study was powered 356 
for changes in muscle NFκB expression and therefore likely underpowered for 357 
detection of body composition, functional and clinical differences within and between 358 
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groups. However, such measures were not the primary aim of the current study, with 359 
previous research documenting significant reductions in many of these variables after 360 
major abdominal surgery. Moreover, the sample size required to investigate 361 
differences in LoS and post-operative morbidity would not have been achievable in a 362 
single centre within a meaningful time-frame. Additionally, as the primary focus of the 363 
study was to explore changes in muscle mass and function we did not explore for 364 
serum markers of inflammation, or activation of muscle NFκB, other than white cell 365 
count. Furthermore, despite recruiting sufficient patients for a baseline visit, attrition 366 
throughout the study resulted in failure to retain sufficient participants to achieve the a 367 
priori calculated sample size (in the placebo group only). Despite this, given the clear 368 
lack of significance observed in both primary and secondary outcomes we do not 369 
believe this compromises our findings. Finally, patients were only studied on two acute 370 
study days, with dates chosen to coincide with standard clinical care visits. An 371 
increased number of study days, particularly extending later into the post-operative 372 
period, may have provided more insight into the longer-term effects of EPA 373 
supplementation given around the time of surgical resection. 374 
 375 
In conclusion, despite observing significant increases in serum white cell count and 376 
reductions in LMM and physical function, we found no clinical or functional benefit of 377 
perioperative EPA nutritional supplementation in individuals undergoing curative CRC 378 
resection in the period up to five weeks post-operation. Future studies should explore 379 
higher doses of EPA administered over a prolonged time-frame with assessment visits 380 
planned to give better temporal resolution. 381 
 382 
 383 
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TABLES 479 
Table 1. Patient baseline data  480 
f=Fisher’s exact test t=Student’s t-test m=Mann-Whitney-u test c= Chi-squared test 481 
Categorical variables are presented as frequencies with continuous variables as mean 482 
(SD), or median (inter-quartile range). 483 
 484 
Table 2. Post-operative complications per Clavien-Dindo classification of surgical 485 
complications 486 
 487 
Figure Legends 488 
 489 
 490 
Figure 1. Study CONSORT diagram 491 
 492 
Figure 2. Whole-body lean muscle mass (LMM) before (Preop) and 4-weeks after  493 
(Postop) colorectal cancer resection surgery with (EPA; N=32) or without (placebo; 494 
N=29) perioperative eicosapentaenoic acid supplementation. Statistical analysis via 495 
Student’s t-tests. 496 
 497 
Figure 3. Clinical outcomes (A. maximum temperature, B. white cell count) for 5 498 
postoperative days (POD) after colorectal cancer resection surgery with (EPA; N=32) 499 
or without (placebo; N=29) perioperative eicosapentaenoic acid supplementation. 500 
Analysis via Mann-U-Whitney statistical testing. 501 
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